Literature DB >> 17804392

Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care.

Jack Ansell1, J Jaime Caro, Maribel Salas, Rowena J Dolor, William Corbett, Andrew Hudnut, Saleem Seyal, Noreen D Lordan, Irina Proskorovsky, Gail Wygant.   

Abstract

OBJECTIVE: Anticoagulation quality and record documentation were retrospectively assessed in patients with chronic nonvalvular atrial fibrillation (CNVAF) managed in a routine care setting.
METHODS: Medical record data extraction from physician practices in 4 regions of the United States.
RESULTS: Of 686 patients, 59% had an electrocardiogram confirming CNVAF, 84% listed at least 1 stroke risk factor, and 60% indicated the goal target international normalized ratio (INR). Two thirds of INRs>3.0 or <2.0 had no recorded dose change, nor did 45% of INRs>5.0. Vitamin K was given (3%) or anticoagulation was temporarily discontinued (9%) for INRs>5.0. The median interval of INR testing was 21 days, which decreased to 7 days for INRs> 4.60. Patients spent 58% of the time in therapeutic range.
CONCLUSION: Serious deficiencies in quality and documentation of routine medical care of anticoagulation for patients with CNVAF continue to exist.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804392     DOI: 10.1177/1062860607303003

Source DB:  PubMed          Journal:  Am J Med Qual        ISSN: 1062-8606            Impact factor:   1.852


  2 in total

1.  Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement.

Authors:  Xiliang Zhu; Xijun Xiao; Sheng Wang; Xianjie Chen; Guoqing Lu; Xiaoyang Li
Journal:  Front Cardiovasc Med       Date:  2022-09-09

Review 2.  Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis.

Authors:  Wenbin Fu; Hongyang Guo; Jianping Guo; Kun Lin; Haijun Wang; Yu Zhang; Yutang Wang; Zhaoliang Shan
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2014-12       Impact factor: 2.160

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.